PHATHOM PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Increase (Decrease) in Accounts Receivable of $19.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $16.70M, a 12.13% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $2.60M.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $22.34M, a 25.89% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $4.53M, a 55.44% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $39.33M, a 5.84% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $37.16M, a 2170.01% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $1.64M.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $19.29M 10-Q · filed 2026-07-30 | $41.63M derived: sum of 3 quarters · filed 2026-07-30 | $46.17M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $2.60M 10-Q · filed 2026-04-30 | $24.93M derived: sum of 2 quarters · filed 2026-04-30 | $29.47M derived: sum of 3 quarters · filed 2026-04-30 | $44.36M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $22.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.87M derived: sum of 2 quarters · filed 2026-02-26 | $41.76M derived: sum of 3 quarters · filed 2026-07-30 | $39.33M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $19.43M derived: sum of 2 quarters · filed 2026-07-30 | $16.99M 10-Q · filed 2025-10-30 | $34.74M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $14.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $12.46M 10-Q · filed 2026-07-30 | $30.20M derived: sum of 3 quarters · filed 2026-07-30 | $40.38M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$2.43M 10-Q · filed 2026-04-30 | $15.31M derived: sum of 2 quarters · filed 2026-04-30 | $25.49M derived: sum of 3 quarters · filed 2026-04-30 | $32.48M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $17.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $27.92M derived: sum of 2 quarters · filed 2026-02-26 | $34.92M derived: sum of 3 quarters · filed 2026-02-26 | $37.16M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $17.17M derived: sum of 2 quarters · filed 2025-10-30 | $19.41M 10-Q · filed 2025-10-30 | $21.05M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $9.24M 10-Q · filed 2025-08-07 | $10.88M derived: sum of 3 quarters · filed 2025-08-07 | $10.88M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.24M 10-Q · filed 2025-05-01 | $3.88M derived: sum of 2 quarters · filed 2025-05-01 | $3.88M derived: sum of 3 quarters · filed 2025-05-01 | $3.88M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.64M derived: sum of 2 quarters · filed 2025-03-06 | $1.64M derived: sum of 3 quarters · filed 2025-03-06 | $1.64M 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q/A · filed 2024-06-14 | |||
| 2022-12-31 | $0.00 10-K/A · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |